CASI Pharmaceuticals Inc (NASDAQ: CASI) has reported a loss for its second fiscal quarter (ending June 30) of $-0.52 versus a loss $-0.77 for the same period a year ago. For the latest four quarters through June 30, E.P.S. were $-2.03 versus $-3.04 for the same period a year ago.
Recent Price Action
CASI Pharmaceuticals Inc (NASDAQ: CASI) stock was unchanged 0.0% on 8/16/24. The shares closed at $6.56. However, exceptionally low trading volume at 4% of normal accompanied the flat performance. The stock has been weak relative to the market over the last nine months and has declined -2.8% during the last week.
Current PriceTarget Research Rating
CASI is expected to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
CASI Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. CASI Pharmaceuticals has a poor Power Rating of 24 and a very low Appreciation Score of 5, with the Lowest Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment